Abstract
The pyrazole heterocycle displayed versatile pharmacological activity ranging from anti-inflammatory to antiviral. Herein, we report the synthesis of bis-pyrazole as receptor- interacting protein 1 kinase inhibitor and evaluated for antiproliferative activity against pancreatic cancer line, PANC-1. Among twelve compounds, three candidates displayed the cytotoxicity IC50 value in single digit micromolar concentration. From the preliminary evaluation, the compound 31 emerged as a potential inhibitor with an IC50 = 4.1 µM. The lead compound showed similar inhibitor IC50 value in comparison to the positive control, doxorubicin. The docking studies confirm that these analogs may require further investigation to improve the potency.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
